Interim results in cutaneous melanoma reported an ORR of 63% in eight anti-PD-1-naïve patients who received combination therapy and 38% in 16 patients who previously failed anti-PD-1 therapy [26]. This evidence concerns the gene PDCD1 and cutaneous melanoma.